

Drugs Issues Series 301

Lists addresses and telephone and fax numbers for federal agencies, Congress, and nongovernmental organizations in Washington, D.C.

Drug research and discovery are of critical importance in human health care.

Computational approaches for drug lead discovery and optimization have proven successful in many recent research programs. These methods have grown in their effectiveness not only because of improved understanding of the basic science - the biological events and molecular interactions that define a target for therapeutic intervention - but also because of advances in algorithms, representations, and mathematical procedures for studying such processes. This volume surveys some of those advances. A broad landscape of high-profile topics in computer-assisted molecular design (CAMD) directed to drug design are included. Subject areas represented in the volume include receptor-based applications such as binding energy approximations, molecular docking, and de novo design; non-receptor-based applications such as molecular similarity; molecular dynamics simulations; solvation and partitioning of a solute between aqueous and nonpolar media; graph theory; non-linear multidimensional optimization, processing of information obtained from simulation studies, global optimization and search strategies, and performance enhancement through parallel computing.

Representatives from industry, academia and government discuss issues related to testing for drug abuse liability and dependence potential. Contributors critically assess current methods for evaluating drugs in human subjects and describe both the advantages and limitations of each approach. This information permits identification of areas in which further research and development are needed.

Textbook of Palliative Medicine provides an alternative, truly international approach to this rapidly growing specialty. This textbook fills a niche with its evidence-based, multi-professional approach and global perspective ensured by the international team of editors and contributing authors. In the absence of an international curriculum for the study of palliative medicine, this textbook provides essential guidance for those both embarking upon a career in palliative medicine or already established in the field, and the structure and content have been constructed very much with this in mind. With an emphasis on providing a service anywhere in the world, including the important issue of palliative care in the developing nations, Textbook of Palliative Medicine offers a genuine alternative to the narrative approach of its competitors, and is an ideal complement to them. It is essential reading for all palliative care physicians in training and in practice, as well as palliative care nurses and other health professionals in the palliative care team

Drug development is the process of finding and producing therapeutically useful pharmaceuticals, turning them into safe and effective medicine, and producing reliable

information regarding the appropriate dosage and dosing intervals. With regulatory authorities demanding increasingly higher standards in such developments, statistics has become an intrinsic and critical element in the design and conduct of drug development programmes. *Statistical Issues in Drug Development* presents an essential and thought provoking guide to the statistical issues and controversies involved in drug development. This highly readable second edition has been updated to include: Comprehensive coverage of the design and interpretation of clinical trials. Expanded sections on missing data, equivalence, meta-analysis and dose finding. An examination of both Bayesian and frequentist methods. A new chapter on pharmacogenomics and expanded coverage of pharmaco-epidemiology and pharmaco-economics. Coverage of the ICH guidelines, in particular ICH E9, *Statistical Principles for Clinical Trials*. It is hoped that the book will stimulate dialogue between statisticians and life scientists working within the pharmaceutical industry. The accessible and wide-ranging coverage make it essential reading for both statisticians and non-statisticians working in the pharmaceutical industry, regulatory bodies and medical research institutes. There is also much to benefit undergraduate and postgraduate students whose courses include a medical statistics component.

PDR Supplement A publishes in June. Supplement B publishes in October. Sold Only as a set. (ISBN: 1-56363-600-X).

Includes a variety of series, each concentrating on a special topic.

The Washington Information Directory (WID) is a topically organized reference resource that lists contact information for federal agencies and nongovernmental organizations in the Washington metro area along with a brief paragraph describing what each organization does

related to that topic. In addition, WID pulls together 55 organization charts for federal agencies, congressional resources related to each chapter topic, hotline and contact information for various specific areas of interest (from Food Safety Resources to internships in Washington), and an extensive list of active congressional caucuses and contact details. WID has two appendices, one with thorough information on congresspersons and committees, and the second with governors and embassies.

Critical Issues in Alcohol and Drugs of Abuse Testing, Second Edition, addresses the general principles and technological advances for measuring drugs and alcohol, along with the pitfalls of drugs of abuse testing. Many designer drugs, for example, are not routinely tested in drugs of abuse panels and may go undetected in a drug test. This updated edition is a must-have for clinical pathologists, toxicologists, clinicians, and medical review officers and regulators, bridging the gap between technical and clinical information. Topics of note include the monitoring of pain management drugs, bath salts, spices (synthetic marijuana), designer drugs and date rape drugs, and more. Serves as a ready resource of information for alcohol and drug testing. Ideal resource for making decisions related to the monitoring and interpretation of results. Includes concise content for clinical laboratory scientists, toxicologists and clinicians. What are the effects of psychoactive drugs on aspects of human behaviour, such as creativity, memory and sexuality? How effective are such drugs in treating mental disorders? How are new drugs tested and licensed? An intriguing introduction to the study of psychopharmacology, this fully revised and updated edition of *Drugs and Behavior* presents a unique analysis of the ways in which human behaviour is affected by drugs, rather than simply by categories of drugs. The text covers the principles of neurotransmission, pharmacokinetics and drug classification.

Issues of new drug development, including drug dangers and benefits, legalization and the prevention and treatment of drug abuse, are also discussed.

Drug addiction is a complex illness. It is characterized by intense and, at times, uncontrollable drug craving, along with compulsive drug seeking and use that persist even in the face of devastating consequences. This update of the National Institute on Drug Abuse's Principles of Drug Addiction Treatment is intended to address addiction to a wide variety of drugs, including nicotine, alcohol, and illicit and prescription drugs. It is designed to serve as a resource for healthcare providers, family members, and other stakeholders trying to address the myriad problems faced by patients in need of treatment for drug abuse or addiction. Addiction affects multiple brain circuits, including those involved in reward and motivation, learning and memory, and inhibitory control over behavior. That is why addiction is a brain disease. Some individuals are more vulnerable than others to becoming addicted, depending on the interplay between genetic makeup, age of exposure to drugs, and other environmental influences. While a person initially chooses to take drugs, over time the effects of prolonged exposure on brain functioning compromise that ability to choose, and seeking and consuming the drug become compulsive, often eluding a person's self-control or willpower. But addiction is more than just compulsive drug taking-it can also produce far reaching health and social consequences. For example, drug abuse and addiction increase a person's risk for a variety of other mental and physical illnesses related to a drug-abusing lifestyle or the toxic effects of the drugs themselves. Additionally, the dysfunctional behaviors that result from drug abuse can interfere with a person's normal functioning in the family, the workplace, and the broader community. Because drug abuse and addiction have so many dimensions and disrupt so many aspects of an

individual's life, treatment is not simple. Effective treatment programs typically incorporate many components, each directed to a particular aspect of the illness and its consequences. Addiction treatment must help the individual stop using drugs, maintain a drug-free lifestyle, and achieve productive functioning in the family, at work, and in society. Because addiction is a disease, most people cannot simply stop using drugs for a few days and be cured. Patients typically require long-term or repeated episodes of care to achieve the ultimate goal of sustained abstinence and recovery of their lives. Indeed, scientific research and clinical practice demonstrate the value of continuing care in treating addiction, with a variety of approaches having been tested and integrated in residential and community settings.

Illegal Drug Use Issues Series Defining Drug Courts The Key Components Research Issues Harm Reduction Evidence, Impacts, and Challenges

The 2018 World Drug Report will include an updated overview of recent trends on production, trafficking and consumption of key illicit drugs as well as highlighting a thematic area of concern. The Report contains a global overview of the baseline data and estimates on drug demand and supply and it provides the reference point of information on the drug situation worldwide. The thematic focus of the 2018 Report will present information and issues related to drugs and women, youth and older people.

Ampia trattazione sulle possibilità terapeutiche nell'ambito della tossicodipendenza, sia da sostanze legali che illegali (eroina, cocaina, anfetamina, cannabis). Si illustra il panorama legislativo e terapeutico europeo e mondiale, così come la prospettiva etica e futura delle diverse forme di terapia. La seconda parte del volume indaga la riduzione

del danno nel campo delle droghe legali (tabacco, alcol), proseguendo poi ad analizzare il rapporto fra terapia e uso ricreativo giovanile della droga. Segue un capitolo dedicato ai problemi legali e criminali nella dipendenza e nel recupero, per poi accennare alle prospettive del recupero nell'Unione Europea.

One of the goals of the Nat. Institute on Drug Abuse is to help the public understand the causes of drug abuse and to prevent its onset. This is a summary of topics covered in the newest ed. of the guide, "Preventing Drug Use Among Children and Adolescents", which includes updated principles, new questions and answers, new program information, and expanded references and resources. This In Brief edition summarizes sections of the guide for community use. Chapters: Prevention Principles; Risk Factors and Protective Factors; Planning for Drug Abuse Prevention in the Community; Applying Prevention Principles to Drug Abuse Prevention Programs; Examples of Research-Based Drug Abuse Prevention Programs; and Selected Resources and References.

The Washington Information Directory is the essential one-stop source for information on U.S. governmental and nongovernmental agencies and organizations. Organized topically, this thoroughly researched guide provides capsule descriptions and contact information that help users quickly and easily find the right person at the right organization. The Washington Information Directory offers three easy ways to find information: by name, by organization, and through detailed subject indexes. It focuses

on the Washington metropolitan area—an organization must have an office in Washington to be listed. It also includes dozens of resource boxes on particular topics, organization charts for all federal agencies, and information about the FOIA and privacy legislation. With more than 10,000 listings and coverage of evolving presidential administration, the 2018–2019 Edition features contact information for the following: Congress and federal agencies Nongovernmental organizations Policy groups and political action committees Foundations and institutions Governors and other state officials U.S. ambassadors and foreign diplomats Congressional caucuses Harm reduction programmes accept the reality of drug use while attempting to reduce its harmful consequences to individuals and society. Here, contributors discuss the philosophical basis and history of such policies and examine their outcomes.

[Copyright: 6d844b80a88d8fe4dcaefc0455b946ec](#)